Cargando…
Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978277/ https://www.ncbi.nlm.nih.gov/pubmed/36862321 http://dx.doi.org/10.1007/s10875-023-01457-z |
| _version_ | 1784899484805758976 |
|---|---|
| author | Johnson, Sarah McDonnell, John C. Fernandez, James M. |
| author_facet | Johnson, Sarah McDonnell, John C. Fernandez, James M. |
| author_sort | Johnson, Sarah |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9978277 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Springer US |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-99782772023-03-02 Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity Johnson, Sarah McDonnell, John C. Fernandez, James M. J Clin Immunol Letter to Editor Springer US 2023-03-02 /pmc/articles/PMC9978277/ /pubmed/36862321 http://dx.doi.org/10.1007/s10875-023-01457-z Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2023 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
| spellingShingle | Letter to Editor Johnson, Sarah McDonnell, John C. Fernandez, James M. Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity |
| title | Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity |
| title_full | Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity |
| title_fullStr | Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity |
| title_full_unstemmed | Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity |
| title_short | Efficacy of Tixagevimab and Cilgavimab Against SARS-CoV-2 Infections in Patients with Inborn Errors of Immunity |
| title_sort | efficacy of tixagevimab and cilgavimab against sars-cov-2 infections in patients with inborn errors of immunity |
| topic | Letter to Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978277/ https://www.ncbi.nlm.nih.gov/pubmed/36862321 http://dx.doi.org/10.1007/s10875-023-01457-z |
| work_keys_str_mv | AT johnsonsarah efficacyoftixagevimabandcilgavimabagainstsarscov2infectionsinpatientswithinbornerrorsofimmunity AT mcdonnelljohnc efficacyoftixagevimabandcilgavimabagainstsarscov2infectionsinpatientswithinbornerrorsofimmunity AT fernandezjamesm efficacyoftixagevimabandcilgavimabagainstsarscov2infectionsinpatientswithinbornerrorsofimmunity |